KOREA PHARMA Co., Ltd. (KOSDAQ: 032300)
South Korea
· Delayed Price · Currency is KRW
15,300
-420 (-2.67%)
Dec 20, 2024, 1:51 PM KST
KOREA PHARMA Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
Operating Revenue | 79,799 | 83,240 | 81,029 | 79,577 | 71,510 | 66,136 | Upgrade
|
Other Revenue | -0 | -0 | -0 | - | - | - | Upgrade
|
Revenue | 79,799 | 83,240 | 81,029 | 79,577 | 71,510 | 66,136 | Upgrade
|
Revenue Growth (YoY) | -5.62% | 2.73% | 1.83% | 11.28% | 8.12% | 9.34% | Upgrade
|
Cost of Revenue | 45,120 | 46,337 | 45,614 | 43,679 | 37,365 | 33,051 | Upgrade
|
Gross Profit | 34,678 | 36,903 | 35,415 | 35,898 | 34,145 | 33,085 | Upgrade
|
Selling, General & Admin | 25,258 | 25,938 | 24,983 | 24,502 | 21,802 | 22,251 | Upgrade
|
Research & Development | 2,461 | 2,313 | 2,452 | 4,893 | 6,221 | 2,680 | Upgrade
|
Other Operating Expenses | 533.44 | 561.44 | 622.52 | 611.61 | 542.74 | 392.3 | Upgrade
|
Operating Expenses | 30,211 | 31,063 | 29,228 | 30,883 | 29,541 | 25,870 | Upgrade
|
Operating Income | 4,467 | 5,840 | 6,187 | 5,014 | 4,604 | 7,215 | Upgrade
|
Interest Expense | -2,695 | -3,738 | -3,867 | -908.17 | -435.67 | -558.46 | Upgrade
|
Interest & Investment Income | 1,423 | 510.74 | 211.94 | 57.42 | 17.28 | 61.26 | Upgrade
|
Earnings From Equity Investments | -1,781 | -1,724 | - | - | - | - | Upgrade
|
Currency Exchange Gain (Loss) | -41.35 | -39.62 | 26.82 | 18.41 | -43.66 | -32.8 | Upgrade
|
Other Non Operating Income (Expenses) | 645.31 | -139.55 | -4,378 | 1,019 | -382.76 | 214.54 | Upgrade
|
EBT Excluding Unusual Items | 2,018 | 710.03 | -1,819 | 5,201 | 3,759 | 6,900 | Upgrade
|
Gain (Loss) on Sale of Investments | 987.1 | 1,910 | -42.2 | 1.93 | 9.11 | 38.64 | Upgrade
|
Gain (Loss) on Sale of Assets | 0.97 | 0.32 | 81.9 | 5.29 | - | 18.98 | Upgrade
|
Asset Writedown | -885.66 | -606.42 | - | - | - | - | Upgrade
|
Pretax Income | 2,120 | 2,014 | -1,780 | 5,208 | 3,768 | 6,958 | Upgrade
|
Income Tax Expense | -880.01 | 1,931 | -660.63 | -1,160 | 608.75 | 1,430 | Upgrade
|
Net Income | 3,000 | 83.76 | -1,119 | 6,368 | 3,159 | 5,528 | Upgrade
|
Net Income to Common | 3,000 | 83.76 | -1,119 | 6,368 | 3,159 | 5,528 | Upgrade
|
Net Income Growth | - | - | - | 101.59% | -42.85% | 44.40% | Upgrade
|
Shares Outstanding (Basic) | 11 | 11 | 11 | 11 | 10 | 9 | Upgrade
|
Shares Outstanding (Diluted) | 12 | 12 | 11 | 11 | 10 | 9 | Upgrade
|
Shares Change (YoY) | 11.10% | 11.22% | -1.22% | 12.80% | 10.95% | 1.93% | Upgrade
|
EPS (Basic) | 275.40 | 7.68 | -103.00 | 584.00 | 324.00 | 629.00 | Upgrade
|
EPS (Diluted) | 275.40 | 7.68 | -103.00 | 579.00 | 324.00 | 629.00 | Upgrade
|
EPS Growth | - | - | - | 78.70% | -48.49% | 41.67% | Upgrade
|
Free Cash Flow | 4,723 | 3,288 | 5,815 | 4,640 | -2,848 | 6,197 | Upgrade
|
Free Cash Flow Per Share | 391.26 | 272.12 | 535.19 | 421.86 | -292.05 | 705.12 | Upgrade
|
Gross Margin | 43.46% | 44.33% | 43.71% | 45.11% | 47.75% | 50.03% | Upgrade
|
Operating Margin | 5.60% | 7.02% | 7.64% | 6.30% | 6.44% | 10.91% | Upgrade
|
Profit Margin | 3.76% | 0.10% | -1.38% | 8.00% | 4.42% | 8.36% | Upgrade
|
Free Cash Flow Margin | 5.92% | 3.95% | 7.18% | 5.83% | -3.98% | 9.37% | Upgrade
|
EBITDA | 7,259 | 8,653 | 8,567 | 7,391 | 6,824 | 8,860 | Upgrade
|
EBITDA Margin | 9.10% | 10.40% | 10.57% | 9.29% | 9.54% | 13.40% | Upgrade
|
D&A For EBITDA | 2,791 | 2,813 | 2,380 | 2,377 | 2,221 | 1,644 | Upgrade
|
EBIT | 4,467 | 5,840 | 6,187 | 5,014 | 4,604 | 7,215 | Upgrade
|
EBIT Margin | 5.60% | 7.02% | 7.64% | 6.30% | 6.44% | 10.91% | Upgrade
|
Effective Tax Rate | - | 95.84% | - | - | 16.16% | 20.55% | Upgrade
|
Advertising Expenses | - | 1,569 | 1,224 | 858.02 | 588.21 | 620.12 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.